NCT05648526View on ClinicalTrials.gov

Neuroprotective Effects of ACTH4-10PRO8-GLY9-PRO10

NACompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

August 1, 2021

Primary Completion Date

September 30, 2021

Study Completion Date

October 30, 2021

Conditions
Ketamine-Induced Neurotoxicity
Interventions
DRUG

ACTH4-10Pro8-Gly9-Pro10

ACTH4-10Pro8-Gly9-Pro10 also has neuromodulator characteristics to function as a neuroprotector in inhibiting the apoptotic process. Modulation by ACTH4-10Pro8-Gly9-Pro10 will increase the levels of BDNF thereby inhibiting the process of apoptosis

DRUG

Ketamine

negative-positive control (ketamine 40 mg/kg BW subcutaneously)

Trial Locations (1)

20155

Faculty of Medicine Universitas Sumatera Utara, Medan

All Listed Sponsors
lead

Universitas Sumatera Utara

OTHER

NCT05648526 - Neuroprotective Effects of ACTH4-10PRO8-GLY9-PRO10 | Biotech Hunter | Biotech Hunter